Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of
cancer-related death. Early detection of prostate cancer is largely determined by a widely …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an
initial diagnosis of prostate cancer and management options for localized, regional, and …

Background Improved clinical predictors for disease progression are needed for localised
prostate cancer, since only a subset of patients develop recurrent or refractory disease after …

Background Risk prediction models that incorporate biomarkers and clinicopathologic
variables may be used to improve decision making after radical prostatectomy (RP). We …

Context Given the highly variable behavior and clinical course of prostate cancer (PCa) and
the multiple available treatment options, a personalized approach to oncologic risk …

Prostate cancer exhibits intra-tumoral heterogeneity that we hypothesize to be the leading
confounding factor contributing to the underperformance of the current pre-treatment clinical …

Results Limited specificity of the prostate-specific antigen (PSA) test brings a need to
develop new and better diagnostic tools. In the last few years, new approaches for providing …

Current tendencies in the treatment course of prostate cancer patients increase the need for
reliable biomarkers that help in decision-making in a challenging clinical setting. Within the …